Johnson & Johnson (NY:JNJ)

256.03 -2.63 (-1.02%)

Official Closing Price Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2

...

14 15 16 17 18 19 20 21 22

...

99 100 Next >

This 2.4%-Yielding Dividend King Remains As Healthy As Ever ↗

January 22, 2026

Johnson & Johnson had a strong year.

Via The Motley Fool

Topics Bonds

S&P 500 Jumps Over 1% As Trump Withdraws EU Tariff Threat: Investor Sentiment Improves, Fear & Greed Index Remains In 'Neutral' Zone ↗

January 22, 2026

U.S. stocks rise as Trump withdraws tariff threats, Johnson & Johnson beats earnings expectations, and all S&P sectors close positively.

Via Benzinga

Topics Government Stocks World Trade

Is This Dividend King Stock a Buy After a Major Development? ↗

January 21, 2026

After a strong performance in 2025, Johnson & Johnson is starting the new year right.

Via The Motley Fool

Topics Government World Trade

J&J Forecasts $100 Billion Milestone for 2026 as Trump Drug Pricing Deals Reshape the Pharma Landscape

January 21, 2026

NEW BRUNSWICK, N.J. — In a landmark display of resilience and strategic pivoting, Johnson & Johnson (NYSE: JNJ) reported fourth-quarter 2025 revenues of $24.56 billion on Wednesday, January 21, 2026,...

Via MarketMinute

Topics Earnings Economy Government

Johnson & Johnson (NYSE:JNJ) Beats Q4 Estimates but Stock Dips on 2026 Guidance ↗

January 21, 2026

Via Chartmill

Johnson & Johnson (NYSE:JNJ) Stands Out as a Dependable Dividend Stock ↗

January 15, 2026

Via Chartmill

Johnson & Johnson (JNJ) Earnings Call Transcript ↗

January 21, 2026

Johnson & Johnson (JNJ) Earnings Call Transcript

Via The Motley Fool

Topics Earnings World Trade

Discover the top S&P500 movers in Wednesday's pre-market session. ↗

January 21, 2026

Via Chartmill

Johnson & Johnson Posts Q4 2025 Revenue Beat, EPS Comes Up Short ↗

January 21, 2026

Johnson & Johnson reported Q4 2025 revenue of $24.6 billion, beating expectations, while EPS came in at $2.46, just below forecasts.

Via Talk Markets

Johnson & Johnson reports Q4 and Full-Year 2025 results

January 21, 2026

From Johnson & Johnson

Via Business Wire

Nasdaq, S&P 500 Futures Rebound, All Eyes On Trump’s Davos Speech: Why TSLA, NVDA, NFLX, AVR Are On Traders' Radar Today ↗

January 21, 2026

Retail sentiment on Stocktwits on SPY and QQQ turned ‘extremely bearish’.

Via Stocktwits

Topics Artificial Intelligence ETFs Economy

Dow, Nasdaq, S&P 500 Futures Tick Higher After Wall Street’s Worst Day In 3 Months: Why NFLX, AAPL, CRVS, GME, UAL Are In Focus Today ↗

January 20, 2026

Via Stocktwits

Topics Stocks

The Titan’s Balance: Johnson & Johnson Reaches Record Highs Amidst Legal Hurdles and Med-Tech Transformation

January 20, 2026

As the healthcare industry looks toward 2026, Johnson & Johnson (NYSE: JNJ) stands at a historic crossroads, reinforcing its reputation as the ultimate bellwether for the global healthcare sector. On...

Via MarketMinute

Topics Bankruptcy Lawsuit World Trade

The New Titan of Wellness: Kimberly-Clark’s $48.7 Billion Kenvue Acquisition Reshapes Consumer Staples

January 20, 2026

In a bold move to transcend its identity as a legacy paper commodities giant, Kimberly-Clark (NYSE: KMB) has launched a massive $48.7 billion bid to acquire Kenvue (NYSE: KVUE), the consumer health...

Via MarketMinute

Topics Initial Public Offering Supply Chain

The M&A Renaissance: 2026 Set to Eclipse a Record-Breaking 2025 as AI and Regulatory Clarity Drive Deal Supercycle

January 20, 2026

As the global financial markets enter the first month of 2026, the dealmaking environment has shifted from a tentative recovery into a full-scale renaissance. Following a monumental 2025 that saw...

Via MarketMinute

Topics Artificial Intelligence Credit Cards Economy

The High-Stakes Balancing Act: Johnson & Johnson Braces for Q4 Earnings Amid Patent Cliffs and MedTech Expansion

January 20, 2026

As the opening bell approaches on January 21, 2026, all eyes on Wall Street are fixed on Johnson & Johnson (NYSE: JNJ), which is set to report its fourth-quarter and full-year 2025 financial results....

Via MarketMinute

Topics Bankruptcy Earnings Economy

Johnson & Johnson Near 52-Week High As CAPLYTA Data Boosts Sentiment ↗

January 20, 2026

Johnson & Johnson's stock approaches its 52-week high due to positive Phase 3 CAPLYTA trial data, strong earnings momentum, and favorable market sentiment as it nears an upcoming earnings report.

Via Talk Markets

How To Earn $500 A Month From Johnson & Johnson Stock Ahead Of Q4 Earnings ↗

January 20, 2026

Johnson & Johnson (NYSE: JNJ) to release Q4 earnings on Jan. 21, with analysts expecting $2.47/share. Recent news includes positive results for cancer drug and dividend yield of 2.38%.

Via Benzinga

Option Volatility And Earnings Report For January 20 - 23

January 20, 2026

Earnings season ramps up this week with some big names set to report. This week we have Netflix, Intel, Johnson & Johnson, Freeport McMoran and 3M Company all reporting in what shapes as a busy and...

Via Barchart.com

Johnson & Johnson's $10 Billion Test: 2026 Outlook Could Make Or Break JNJ Heading Into Q4 ↗

January 20, 2026

Johnson & Johnson is set to report its Q4 results on Wednesday, facing one of the most important transitions in its modern history.

Via Benzinga

The New Era of Johnson & Johnson: A 2026 Deep-Dive Research Feature

January 19, 2026

As of January 19, 2026, Johnson & Johnson (NYSE: JNJ) stands as a radically different enterprise than the one most investors recognized just three years ago. Following the successful spin-off of its...

Via Finterra

Topics Artificial Intelligence Bankruptcy Economy

Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever ↗

January 19, 2026

Income investors can rely on these stocks.

Via The Motley Fool

Topics Intellectual Property

Wall Street’s Comeback King: Citigroup Shatters M&A Records as Jane Fraser Sets a High Bar for 2026

January 16, 2026

Citigroup Inc. (NYSE: C) has emerged from its multi-year restructuring with a historic performance in its investment banking division, reporting record-breaking M&A advisory revenue for the 2025 fiscal...

Via MarketMinute

Topics Artificial Intelligence Economy

Wall Street Renaissance: Goldman Sachs Posts Record $9.3 Billion in Fees as Dealmaking Roars Back

January 16, 2026

On January 15, 2026, Goldman Sachs (NYSE: GS) silenced critics of its strategic pivot by reporting a powerhouse fourth-quarter performance for 2025, headlined by a staggering $9.34 billion in annual...

Via MarketMinute

Topics Credit Cards Earnings Economy

Citigroup Shakes Up Wall Street with Record M&A Revenue as Global Dealmaking Thaws

January 15, 2026

In a definitive signal that the era of stagnant dealmaking has come to a close, Citigroup (NYSE:C) has reported record-breaking M&A advisory revenue for the fiscal year 2025. The results, unveiled on...

Via MarketMinute

Topics Economy

"Animal Spirits" Return: Morgan Stanley Signals M&A Renaissance as Healthcare and Industrials Lead Shifting Landscape

January 15, 2026

As 2026 begins, the global mergers and acquisitions (M&A) market is witnessing a profound "renaissance," driven by a confluence of stabilizing interest rates, record levels of corporate cash, and a...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

Johnson & Johnson Drug Slows Blood Cancer, Extends Survival In Pretreated Patients ↗

January 15, 2026

Johnson & Johnson reports Phase 3 results showing Tecvayli reduced disease progression and deaths in multiple myeloma patients, beating standard treatments with manageable side effects.

Via Benzinga

Topics Death

Healthcare Titan Ascendant: Johnson & Johnson Hits All-Time Highs as It Navigates a New Political and Clinical Era

January 15, 2026

As of January 15, 2026, Johnson & Johnson (NYSE: JNJ) has emerged as the undisputed pacesetter of the healthcare sector, with its stock price surging to an all-time high of $218.53. This milestone...

Via MarketMinute

Topics Artificial Intelligence Bankruptcy Earnings

FDA Reversal Sends Atara Biotherapeutics into Tailspin: Stock Plummets 67% on Second CRL for Tabelecleucel

January 14, 2026

In a stunning blow to the burgeoning field of allogeneic cell therapy, Atara Biotherapeutics (Nasdaq: ATRA) saw its market valuation evaporate this week following a second Complete Response Letter...

Via MarketMinute

Topics Bankruptcy

US Current Account Deficit Narrows to $226.4 Billion in Q3 2025: An Analysis of the Shift

January 14, 2026

The United States current account deficit narrowed significantly in the third quarter of 2025, falling to $226.4 billion, or approximately 2.9% of the nation’s gross domestic product (GDP). This marks...

Via MarketMinute

Topics Economy World Trade

< Previous 1 2

...

14 15 16 17 18 19 20 21 22

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.